Business Insider

Chembio Diagnostics Receives WHO Prequalification Approval for HIV Self-Test

MEDFORD, N.Y., Nov. 04, 2019 (GLOBE NEWSWIRE) -- November 4, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today ...
Newsday

Sale of test maker Chembio clears bar for shareholder approval on fourth try

The sale of Chembio Diagnostics Inc. in Medford and Bay Shore to a French firm has finally been completed, the companies announced this week. A slim majority of 50.9% of Chembio shares were tendered ...
Seeking Alpha

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U ...
Nasdaq

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

HAUPPAUGE, N.Y., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its ...
Nasdaq

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

HAUPPAUGE, N.Y., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the submission ...
Newsday

LI test maker wins $2.7 million judgment against UK firm that stole HIV self-test technology

A Hauppauge manufacturer of HIV tests has won a $2.7 million judgment against a former distributor in the United Kingdom. Chembio Diagnostics Inc. said this week that an arbitration tribunal found its ...
Business Insider

Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis SystemU.S. Regulatory Submission for DPP® HIV-Syphilis System Expected in Q1 2018

MEDFORD, N.Y., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced completion of the ...
Staten Island Advance

FDA revokes Chembio emergency use authorization, stunting Borough Hall testing partnership

STATEN ISLAND, N.Y. -- The Food and Drug Administration (FDA) revoked Chembio’s emergency use authorization for its coronavirus (COVID-19) antibody test — nearly two months after Borough Hall forged a ...
Business Wire

ROSEN, A LEADING LAW FIRM, Reminds Chembio Diagnostics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12, 2020 and June 16, 2020, ...
Reuters

Chembio Diagnostics beats securities fraud claims over COVID-19 test

(Reuters) - A U.S. judge has dismissed claims that Chembio Diagnostics Inc defrauded investors by overstating the accuracy of its COVID-19 antibody test in the early months of the pandemic, but will ...
MarketWatch

Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test

Shares of Chembio Diagnostics Inc. skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S. exchanges, in the wake of the point-of-care diagnostics ...